{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:36Z","timestamp":1791497916946,"version":"4.3.4"},"reference-count":146,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1124\/dmd.122.000856","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:54:50Z","timestamp":1669769690000},"page":"360-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine"],"prefix":"10.1016","volume":"51","author":[{"given":"Elaine E.","family":"To","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1124\/dmd.122.000856_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-20","article-title":"Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens","volume":"64","author":"Abdalla","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1124\/dmd.122.000856_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/pathogens8040213","article-title":"The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review","volume":"8","author":"Al Mana","year":"2019","journal-title":"Pathogens"},{"key":"10.1124\/dmd.122.000856_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0149-2918(95)80107-3","article-title":"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients","volume":"17","author":"Anderson","year":"1995","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.122.000856_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"10.1124\/dmd.122.000856_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.000856_bib7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase i\/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1089\/hum.1995.6.12-1525","article-title":"The thymidine kinase\/ganciclovir-mediated \u201csuicide\u201d effect is variable in different tumor cells","volume":"6","author":"Beck","year":"1995","journal-title":"Hum Gene Ther"},{"key":"10.1124\/dmd.122.000856_bib9","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.39.7.1546","article-title":"Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults","volume":"39","author":"Beutner","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.000856_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/AAC.00968-06","article-title":"Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131","volume":"51","author":"Birkus","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1A","key":"10.1124\/dmd.122.000856_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9343(82)90128-0","article-title":"Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus","volume":"73","author":"Biron","year":"1982","journal-title":"Am J Med"},{"key":"10.1124\/dmd.122.000856_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078814","article-title":"Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells","volume":"8","author":"Biswas","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.000856_bib14","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1128\/AAC.03270-14","article-title":"Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract","volume":"58","author":"Biswas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00430-011-0191-4","article-title":"Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and\/or foscarnet","volume":"200","author":"Bleymehl","year":"2011","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"10.1124\/dmd.122.000856_bib16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"key":"10.1124\/dmd.122.000856_bib17","first-page":"207","article-title":"Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection","volume":"8","author":"Bras","year":"2001","journal-title":"Can J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000856_bib18","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","article-title":"Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals","volume":"54","author":"Burrel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.122.000856_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1124\/dmd.122.000856_bib21","unstructured":"CDC (2012) CDC Statement on FDA Approval of Drug for HIV Prevention, cdc.gov."},{"key":"10.1124\/dmd.122.000856_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/imr.12063","article-title":"HIV and co-infections","volume":"254","author":"Chang","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1124\/dmd.122.000856_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jop.12534","article-title":"Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta-analysis","volume":"46","author":"Chen","year":"2017","journal-title":"J Oral Pathol Med"},{"key":"10.1124\/dmd.122.000856_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/095632029500600403","article-title":"Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases \u03b1, \u03b2 and \u03b3","volume":"6","author":"Cherrington","year":"1995","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"10.1124\/dmd.122.000856_bib25","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000856_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1124\/dmd.122.000856_bib27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/infdis\/172.1.239","article-title":"Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates","volume":"172","author":"Chou","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221082773","article-title":"Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19","volume":"27","author":"Cihlar","year":"2022","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.122.000856_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350701200211","article-title":"Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors","volume":"12","author":"Cihlar","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.122.000856_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11904-020-00499-x","article-title":"Sex Differences in the Treatment of HIV","volume":"17","author":"Cohn","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1124\/dmd.122.000856_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1124\/dmd.122.000856_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1179\/1973947815Y.0000000065","article-title":"The pharmacokinetic basis of oral valacyclovir treatment of herpes simplex virus (HSV) or varicella zoster virus (VZV) meningitis, meningoencephalitis or encephalitis in adults","volume":"29","author":"Cunha","year":"2017","journal-title":"J Chemother"},{"key":"10.1124\/dmd.122.000856_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.105001","article-title":"The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques","volume":"186","author":"Daly","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1124\/dmd.122.000856_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/289081a0","article-title":"Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance","volume":"289","author":"Darby","year":"1981","journal-title":"Nature"},{"issue":"12","key":"10.1124\/dmd.122.000856_bib35","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3390\/v13122410","article-title":"Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections","volume":"13","author":"De Clercq","year":"2021","journal-title":"Viruses"},{"key":"10.1124\/dmd.122.000856_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1627824","article-title":"Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases","volume":"2020","author":"de Melo Silva","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1124\/dmd.122.000856_bib37","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/dmd.122.000856_bib38","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2010.02.001","article-title":"Human and viral nucleoside\/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties","volume":"86","author":"Deville-Bonne","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1124\/dmd.122.000856_bib40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/infdis\/158.2.449","article-title":"Cytomegalovirus infection in patients with AIDS","volume":"158","author":"Drew","year":"1988","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1124\/dmd.122.000856_bib41","first-page":"S42","article-title":"Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance","volume":"4","author":"Drew","year":"1991","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"10.1124\/dmd.122.000856_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8922-5_1","article-title":"Origins of Suicide Gene Therapy","volume":"1895","author":"D\u00fczg\u00fcne\u015f","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.122.000856_bib43","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1081\/NCN-100002496","article-title":"Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood","volume":"20","author":"Eisenberg","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1A","key":"10.1124\/dmd.122.000856_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am J Med"},{"issue":"Suppl B","key":"10.1124\/dmd.122.000856_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/12.suppl_B.9","article-title":"The biochemistry and mechanism of action of acyclovir","volume":"12","author":"Elion","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.122.000856_bib46","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.122.000856_bib47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1124\/dmd.122.000856_bib48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","article-title":"Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1124\/dmd.122.000856_bib49","unstructured":"FDA 2017 GANCICLOVIR INJECTION, for intravenous use, United States Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209347lbl.pdf"},{"key":"10.1124\/dmd.122.000856_bib50","unstructured":"FDA (2019) FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic, United States Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic"},{"key":"10.1124\/dmd.122.000856_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/aid.2017.0243","article-title":"Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells","volume":"34","author":"Figueroa","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1124\/dmd.122.000856_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195764","article-title":"Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067","volume":"13","author":"Figueroa","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.000856_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/106002808902300101","article-title":"Evaluation of ganciclovir for cytomegalovirus disease","volume":"23","author":"Fletcher","year":"1989","journal-title":"DICP"},{"key":"10.1124\/dmd.122.000856_bib54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/AAC.28.2.240","article-title":"Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses","volume":"28","author":"Freitas","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib55","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.49.3.1055-1059.2005","article-title":"Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study","volume":"49","author":"Frobert","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib56","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0149-2918(02)80058-3","article-title":"Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection","volume":"24","author":"Fung","year":"2002","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.122.000856_bib57","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1016\/S0021-9258(17)42739-6","article-title":"Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase","volume":"259","author":"Furman","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.000856_bib58","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.1016\/S0021-9258(17)34236-9","article-title":"Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine","volume":"253","author":"Fyfe","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.000856_bib59","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Gallant","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib60","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32832c96e9","article-title":"Renal function with use of a tenofovir-containing initial antiretroviral regimen","volume":"23","author":"Gallant","year":"2009","journal-title":"AIDS"},{"key":"10.1124\/dmd.122.000856_bib61","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.000856_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab078","article-title":"While We Endure This Pandemic, What New Respiratory Virus Threats Are We Missing?","volume":"8","author":"Gray","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1124\/dmd.122.000856_bib63","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/v13040637","article-title":"Mitigating Future Respiratory Virus Pandemics: New Threats and Approaches to Consider","volume":"13","author":"Gray","year":"2021","journal-title":"Viruses"},{"key":"10.1124\/dmd.122.000856_bib64","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"10.1124\/dmd.122.000856_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/pgs-2018-0140","article-title":"Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir","volume":"20","author":"Hamlin","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.000856_bib66","first-page":"88","article-title":"Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update","volume":"22","author":"Harris","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1124\/dmd.122.000856_bib67","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3171\/jns.2000.92.5.0804","article-title":"Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study","volume":"92","author":"Harsh","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1124\/dmd.122.000856_bib68","unstructured":"Hsu JM, Van Besien K, Glesby MJ, Coletti A, Pahwa SG, Warshaw M, Golner A, Bone F, Tobin N, Riches M et al. (2022) HIV-1 REMISSION WITH CCR5\u039432\u039432 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107, in Conference on Retroviruses and Opportunistic Infections, Virtual."},{"key":"10.1124\/dmd.122.000856_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/aid.2020.0250","article-title":"Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission","volume":"38","author":"Hu","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1124\/dmd.122.000856_bib70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/COH.0000000000000703","article-title":"Renal adverse drug reactions","volume":"16","author":"Hughes","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1124\/dmd.122.000856_bib71","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/rmv.659","article-title":"Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV","volume":"20","author":"Hyde","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1124\/dmd.122.000856_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101539","article-title":"Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells","volume":"71","author":"Ivana","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1124\/dmd.122.000856_bib73","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1592\/phco.29.10.1212","article-title":"Tenofovir for the treatment of hepatitis B virus","volume":"29","author":"Jenh","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.122.000856_bib74","first-page":"1","article-title":"Herpesvirus infections in organ transplant recipients","volume":"10","author":"Jenkins","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1124\/dmd.122.000856_bib75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmii.2021.01.001","article-title":"Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review","volume":"54","author":"Jerry Teng","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1124\/dmd.122.000856_bib76","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.18632\/oncotarget.6737","article-title":"Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma","volume":"7","author":"Ji","year":"2016","journal-title":"Oncotarget"},{"issue":"Suppl_2","key":"10.1124\/dmd.122.000856_bib77","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1093\/cid\/ciab1056","article-title":"Diagnosis and Management of Genital Herpes: Key Questions and Review of the Evidence for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines","volume":"74","author":"Johnston","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib78","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.000856_bib79","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/07388551.2020.1751058","article-title":"Advances in HIV diagnosis and monitoring","volume":"40","author":"Kabir","year":"2020","journal-title":"Crit Rev Biotechnol"},{"key":"10.1124\/dmd.122.000856_bib80","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.000856_bib81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/spid.2002.29754","article-title":"Antiviral therapy for cytomegalovirus infections in pediatric patients","volume":"13","author":"Kimberlin","year":"2002","journal-title":"Semin Pediatr Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib82","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1080\/15257770903155899","article-title":"Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives","volume":"28","author":"Koch","year":"2009","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1124\/dmd.122.000856_bib83","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ebiom.2015.07.008","article-title":"Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner","volume":"2","author":"Lade","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1124\/dmd.122.000856_bib84","doi-asserted-by":"crossref","first-page":"578","DOI":"10.5694\/mja14.00183","article-title":"Cytomegalovirus disease in immunocompetent adults","volume":"201","author":"Lancini","year":"2014","journal-title":"Med J Aust"},{"key":"10.1124\/dmd.122.000856_bib85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/j.1552-4604.1996.tb04193.x","article-title":"Effect of food on the relative bioavailability of oral ganciclovir","volume":"36","author":"Lavelle","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000856_bib86","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib87","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00602-21","article-title":"Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib88","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.16788","article-title":"Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data","volume":"55","author":"Lim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 7","key":"10.1124\/dmd.122.000856_bib89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12594","article-title":"Cytomegalovirus infection in solid organ transplant recipients","volume":"20","author":"Lumbreras","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1124\/dmd.122.000856_bib90","first-page":"335","article-title":"Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis","volume":"9","author":"Ma","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"10.1124\/dmd.122.000856_bib91","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/jac\/dkh244","article-title":"Pharmacokinetics of valaciclovir","volume":"53","author":"MacDougall","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.122.000856_bib92","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/acsmedchemlett.1c00624","article-title":"Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2","volume":"13","author":"Mackman","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"7","key":"10.1124\/dmd.122.000856_bib93","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3390\/ijms23073431","article-title":"40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?","volume":"23","author":"Majewska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.000856_bib94","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/jac\/dkt532","article-title":"Phase I\/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults","volume":"69","author":"Markowitz","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.122.000856_bib95","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic Drug Monitoring of Ganciclovir: Where Are We?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.122.000856_bib96","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/FTD.0000000000000598","article-title":"Ganciclovir Therapeutic Drug Monitoring: A Case Series","volume":"41","author":"M\u00e4rtson","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"Suppl 3","key":"10.1124\/dmd.122.000856_bib97","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1093\/clinids\/10.Supplement_3.S490","article-title":"Antiviral activity and mechanism of action of ganciclovir","volume":"10","author":"Matthews","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib98","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000856_bib99","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/molpharm.121.000348","article-title":"Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro","volume":"100","author":"Mosher","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.000856_bib100","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib101","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years","volume":"21","author":"Nelson","year":"2007","journal-title":"AIDS"},{"key":"10.1124\/dmd.122.000856_bib102","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/cid\/ciz443","volume":"70","author":"Nicol","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib103","series-title":"FDA-Approved HIV Medicines","year":"2022"},{"key":"10.1124\/dmd.122.000856_bib104","article-title":"Topical microbicides for preventing sexually transmitted infections","volume":"3","author":"Obiero","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/dmd.122.000856_bib105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17425247.2022.2020242","article-title":"Drug-releasing vaginal rings for HIV\/STI and pregnancy prevention: a review of recent advances and clinical applications","volume":"19","author":"Palanee-Phillips","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1124\/dmd.122.000856_bib106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib107","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib108","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-virology-092917-043457","article-title":"Antiviral Approaches for the Treatment of Herpes Simplex Virus Infections in Newborn Infants","volume":"5","author":"Poole","year":"2018","journal-title":"Annu Rev Virol"},{"key":"10.1124\/dmd.122.000856_bib109","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11904-012-0119-7","article-title":"Osteoporosis and bone health in HIV","volume":"9","author":"Powderly","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1124\/dmd.122.000856_bib110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.25100\/cm.v48i3.2997","article-title":"Immunotherapy and gene therapy as novel treatments for cancer","volume":"48","author":"Rangel-Sosa","year":"2017","journal-title":"Colomb Med (Cali)"},{"key":"10.1124\/dmd.122.000856_bib111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1124\/dmd.122.000856_bib112","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1128\/AAC.39.10.2304","article-title":"Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells","volume":"39","author":"Robbins","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib113","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib114","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3851\/IMP1870","article-title":"Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2","volume":"16","author":"Sauerbrei","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.122.000856_bib115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.antiviral.2014.03.015","article-title":"Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes","volume":"107","author":"Schubert","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1124\/dmd.122.000856_bib116","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.00889-06","article-title":"Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses","volume":"50","author":"Sergerie","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25405","article-title":"Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men","volume":"22","author":"Shieh","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1124\/dmd.122.000856_bib118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect Chemother"},{"key":"10.1124\/dmd.122.000856_bib119","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618775243","article-title":"Phosphoramidates and phosphonamidates (ProTides) with antiviral activity","volume":"26","author":"Slusarczyk","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1124\/dmd.122.000856_bib120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0006-2952(85)90608-2","article-title":"Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells","volume":"34","author":"Smee","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.000856_bib121","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/514041","article-title":"High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes","volume":"176","author":"Smith","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib122","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Soul-Lawton","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib123","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/infdis\/171.6.1431","article-title":"Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I\/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group","volume":"171","author":"Spector","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib124","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1128\/AAC.35.11.2191","article-title":"Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir","volume":"35","author":"Stanat","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.122.000856_bib126","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4331\/wjbc.v4.i4.91","article-title":"Cathepsins mediate tumor metastasis","volume":"4","author":"Tan","year":"2013","journal-title":"World J Biol Chem"},{"key":"10.1124\/dmd.122.000856_bib127","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials","volume":"93","author":"Tao","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1124\/dmd.122.000856_bib128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.000856_bib129","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fmicb.2019.00952","article-title":"Nucleoside Analogues as Antibacterial Agents","volume":"10","author":"Thomson","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1124\/dmd.122.000856_bib130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAI.0000000000001864","article-title":"Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users","volume":"80","author":"Thurman","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.122.000856_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199778","article-title":"Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women","volume":"13","author":"Thurman","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.000856_bib132","first-page":"419","article-title":"Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment","volume":"6","author":"Tian","year":"2013","journal-title":"OncoTargets Ther"},{"key":"10.1124\/dmd.122.000856_bib133","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00671-07","article-title":"Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro","volume":"51","author":"Tong","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.122.000856_bib134","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000856_bib135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1566523023347733","article-title":"Influence of the bystander effect on HSV-tk\/GCV gene therapy. A review","volume":"2","author":"van Dillen","year":"2002","journal-title":"Curr Gene Ther"},{"key":"10.1124\/dmd.122.000856_bib136","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejps.2012.11.007","article-title":"Selectivity of kinases on the activation of tenofovir, an anti-HIV agent","volume":"48","author":"Varga","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.122.000856_bib137","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1389200217666151210141903","article-title":"Intracellular Metabolism of Nucleoside\/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse Transcriptase","volume":"17","author":"Varga","year":"2016","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.000856_bib138","unstructured":"Vermes K (2016) FDA Approves Vemlidy for Treatment of Chronic Hepatitis B in Adults, Pharmacy Times. https:\/\/www.pharmacytimes.com\/view\/fda-approves-vemlidy-for-treatment-of-chronic-hepatitis-b-in-adults"},{"key":"10.1124\/dmd.122.000856_bib139","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1517\/14656566.2010.494179","article-title":"Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults","volume":"11","author":"Vigil","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/dmd.122.000856_bib140","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.12688\/f1000research.16157.1","article-title":"Clinical management of herpes simplex virus infections: past, present, and future","volume":"7","author":"Whitley","year":"2018","journal-title":"F1000 Res"},{"key":"10.1124\/dmd.122.000856_bib141","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000856_bib142","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","article-title":"Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients","volume":"44","author":"Wiltshire","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 3","key":"10.1124\/dmd.122.000856_bib143","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1093\/clinids\/10.Supplement_3.S547","article-title":"Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients","volume":"10","author":"Winston","year":"1988","journal-title":"Rev Infect Dis"},{"issue":"7","key":"10.1124\/dmd.122.000856_bib144","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3390\/cells9071679","article-title":"The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management","volume":"9","author":"Yadati","year":"2020","journal-title":"Cells"},{"key":"10.1124\/dmd.122.000856_bib145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.virusres.2017.01.019","article-title":"Herpesvirus DNA polymerases: Structures, functions and inhibitors","volume":"234","author":"Zarrouk","year":"2017","journal-title":"Virus Res"},{"key":"10.1124\/dmd.122.000856_bib146","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1134\/S0026893321040105","article-title":"Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action","volume":"55","author":"Zenchenko","year":"2021","journal-title":"Mol Biol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.000856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:59:50Z","timestamp":1739937590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0090955624009450"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.000856","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.000856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}